The new Dual-Color Assays accelerate the pace and expand the biological space in the quest to discover new autoantibody biomarkers.
The Dual-Color IgG/IgA Assays enable the simultaneous and sensitive detection of IgG and IgA autoantibodies with exquisite specificity from very low sample volume input.
Dual-Color Assays Services are now available with all Sengenics protein arrays, which are based on the patented KREX protein folding technology and are designed for highly specific and reproducible discovery of autoantibody biomarkers.
The Dual-Color Assays are powered by expert bioinformatic and machine learning-based data analysis services, leading to the identification of biomarker signatures.
The new Dual-Color Assay Services expand the view of disease biology and accelerate autoantibody biomarker discovery across the autoimmune disease, immuno-oncology and neuroinflammation fields.
The Dual Color IgG/IgA Assay Services expands Sengenics' systems serology tools enabling a deeper dive into the humoral immune response.
Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making.
Its solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval